Screener
Avalo Therapeutics AVTX Invested capital
Discontinued — last reported Q2 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's invested capital?
- Avalo Therapeutics (AVTX) reported invested capital of $363.29M in Q2 2026.
- How has Avalo Therapeutics's invested capital changed year-over-year?
- Avalo Therapeutics's invested capital increased by 479.1% year-over-year, from $62.73M to $363.29M.
- What is the long-term trend for Avalo Therapeutics's invested capital?
- Over 5 years (2020 to 2025), Avalo Therapeutics's invested capital has grown at a 57.6% compound annual growth rate (CAGR), from $6.92M to $67.37M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about Avalo Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude